A Randomised, Double-blind (Sponsor Open), Placebo-controlled, Three Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single (in Both Fed and Fasted States) or Repeat Doses of GSK3358699 in Healthy Male Participants
Phase of Trial: Phase I
Latest Information Update: 15 Oct 2019
Price : $35 *
At a glance
- Drugs GSK-3358699 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; First in man
- Sponsors GlaxoSmithKline
- 09 Oct 2019 Planned End Date changed from 29 Jul 2019 to 24 Sep 2020.
- 09 Oct 2019 Planned primary completion date changed from 29 Jul 2019 to 24 Sep 2020.
- 09 Oct 2019 Status changed from recruiting to suspended.